TLDR
- SBC Medical completed its tender offer for Waqoo shares at JPY 1,900 per share
- The company will acquire more than 575,000 shares for about JPY 1.09 billion
- SBC’s voting rights in Waqoo are set to exceed 50% after settlement
- Transaction strengthens SBC’s regenerative medicine and R&D exposure
- Deal supports SBC’s long-term expansion across Japan and global markets
Get live prices, charts, and KO Scores from KnockoutStocks.com, the data-driven platform ranking every stock by quality and breakout potential.
SBC Medical Group Holdings Incorporated (SBC) closed at $4.18, up 1.46%, as the company announced the final results of its tender offer for Waqoo, Inc. shares.
SBC Medical Group Holdings Incorporated, SBC
The completion of the transaction marks a major milestone for SBC Medical, positioning it as the parent company and largest shareholder of the Japan-based regenerative medicine firm. Investors are closely watching the move as part of SBC’s broader push to deepen its healthcare technology footprint in Asia.
The tender offer began on November 14, 2025, and concluded on December 12, 2025, with an offer price of JPY 1,900 per share. SBC Medical confirmed it will acquire 575,052 common shares of Waqoo, with settlement scheduled to begin on December 19, 2025. The total investment is expected to reach approximately JPY 1.09 billion, aligning with the company’s stated strategy to enhance its medical research and development capabilities.
Tender Offer Results and Ownership Shift
The tender offer attracted strong interest, with 637,817 shares tendered, exceeding the maximum planned purchase volume. SBC Medical applied a pro rata allocation method in line with Japanese regulations. Before the transaction, SBC Medical held 9.49% of Waqoo’s voting rights. After settlement, its direct ownership is expected to rise to 24.93%, while special related parties will retain 26.58%. Combined with an off-market transfer of remaining shares from Waqoo’s largest shareholder, Yoshiyuki Aikawa, SBC Medical’s voting rights are expected to exceed 50%, giving it effective control.
This ownership shift allows SBC Medical to consolidate Waqoo as a subsidiary and integrate its regenerative medicine technologies into the group’s service offering. The company stated that the acquisition will enhance its ability to deliver comprehensive solutions to medical practice clients across multiple specialties.
Strategic Rationale and Market Expansion
Waqoo specializes in regenerative medicine technologies and medical R&D, areas that complement SBC Medical’s existing franchise businesses. SBC operates clinics and medical services across aesthetic medicine, dermatology, orthopedics, fertility treatment, dentistry, hair restoration, and ophthalmology. By bringing Waqoo under its umbrella, SBC Medical strengthens its position in advanced healthcare innovation while reinforcing its presence in the Japanese market.
Management views the deal as a key step in expanding healthcare technology capabilities while supporting long-term growth in Asia. Japan remains a strategic market due to its aging population, demand for advanced treatments, and supportive framework for regenerative medicine research.
Settlement for the tendered shares will be handled in cash through SBI Securities Co., Ltd., with payments remitted to shareholders beginning December 19, 2025. The results were formally disclosed through the Tokyo Stock Exchange’s system on December 13, 2025. SBC Medical confirmed there are no changes to the policies or outlook previously outlined in its tender offer registration statement.
Broader Corporate Growth Context
SBC Medical Group Holdings has continued to expand its global profile since its Nasdaq listing in September 2024. In June 2025, the company was added to the Russell 3000® Index, reflecting its growing relevance in U.S. equity markets. The group operates a diversified medical franchise model and is actively expanding in the United States and Asia through direct operations and medical tourism initiatives.
The completion of the Waqoo tender offer reinforces SBC Medical’s stated mission of contributing to global well-being through medical innovation. While near-term financial impacts were not detailed, the acquisition positions the company for longer-term value creation through technology integration, expanded services, and deeper access to the Japanese healthcare ecosystem.
